贝伐珠单抗作为BRCA突变晚期卵巢癌维持治疗:一项大型回顾性多中心病例对照研究
该多中心回顾性病例对照研究纳入441例晚期卵巢癌患者,比较接受与未接受贝伐珠单抗维持治疗者的结局。贝伐珠单抗组中位无进展生存期显著延长4个月(21 vs 17个月,p=.033),但BRCA突变患者中无差异(24 vs 22个月,p=.3),BRCA野生型患者中显著延长(20 vs 15个月,p=.019)。
要点
- 贝伐珠单抗维持治疗使总体人群mPFS延长4个月(21 vs 17个月,p=.033)。
- BRCA突变患者中贝伐珠单抗未显示mPFS获益(24 vs 22个月,p=.3)。
- BRCA野生型患者中贝伐珠单抗显著延长mPFS(20 vs 15个月,p=.019)。
核心结论
- BRCA突变患者中未发现贝伐珠单抗维持治疗在PFS和OS方面的肿瘤学获益证据。
- BRCA野生型患者似乎从抗血管生成治疗中获得mPFS获益。
研究设计与样本
- 多中心回顾性病例对照研究,纳入2015年1月至2019年6月间初治晚期卵巢癌患者。
- 主要纳入标准:接受三周卡铂-紫杉醇一线治疗(联合或不联合贝伐珠单抗维持),且已知BRCA突变状态。
- 共纳入441例患者,183例(41.5%)接受贝伐珠单抗(病例组),258例(58.5%)未接受(对照组)。
主要发现
- 病例组BRCA突变患者58例(39%),对照组90例(34.9%)(p=.77)。
- 接受贝伐珠单抗者中位无进展生存期显著延长4个月(21 vs 17个月,p=.033)。
- BRCA突变患者中,接受与未接受贝伐珠单抗者mPFS无差异(24 vs 22个月,p=.3)。
- BRCA野生型患者中,贝伐珠单抗显著延长mPFS(20 vs 15个月,p=.019)。
- 多因素分析中,PFS延长的独立因素为BRCA状态(OR=0.60)、接受PDS(OR=0.69)和完全细胞减灭(OR=0.50),贝伐珠单抗给药不是独立因素(OR=0.83,p=.22)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to investigate the correlation between BRCA mutational status and response to bevacizumab in a large advanced ovarian cancer (AOC) series. METHODS: This is a multicenter, retrospective case-control study including upfront AOC treated between January 2015 and June 2019. The main inclusion criteria were: having received three weekly carboplatin-paclitaxel as first-line treatment, with or without Bevacizumab maintenance, knowledge of the BRCA mutational status. RESULTS: Overall, 441 patients were included; 183 (41.5%) patients received bevacizumab (Cases), and 258 (58.5%) did not receive it (Controls). The BRCA mutated patients (BRCAmut) were 58 (39%) in the Cases group and 90 (34.9%) in the Controls group (p = .77). Patients who received bevacizumab had a significant 4-months increase in median progression free survival (mPFS: 21 vs. 17 months, p = .033). Concerning BRCAmut patients, no differences were shown between those who received bevacizumab or not in terms of mPFS (24 vs. 22 months, p = .3). Conversely, in BRCA wild-type (BRCAwt) population bevacizumab administration significantly prolonged mPFS (20 vs 15 months, p = .019). At multivariate analysis, independent factors of prolonged PFS were BRCA status (OR = 0.60), having received PDS (OR = 0.69), and complete cytoreduction (OR = 0.50), but not the bevacizumab administration (OR = 0.83, p = .22). CONCLUSIONS: No evidence of oncological benefit in terms of PFS and OS related to bevacizumab maintenance therapy was found in BRCAmut patients. Differently, BRCAwt patients seem to benefit from antiangiogenic treatment in terms of mPFS.
引用
- Lorusso D, Marchetti C, Conte C, et al. Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study. Gynecol Oncol. 2020. PMID: 32703631. doi:10.1016/j.ygyno.2020.07.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。